The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.
Matthew Steven Davids, MD, MMSc
Advertisement
Articles by Matthew Steven Davids, MD, MMSc
The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.
A multicenter phase 2 study of patients with chronic lymphocytic leukemia who developed Richter’s syndrome, presented at the 2020 ASCO Virtual Scientific Program, assessed the use of this treatment combination.
The study evaluated venetoclax plus dose-adjusted R-EPOCH in patients with chronic lymphocytic leukemia who developed Richter’s syndrome.
The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter’s Syndrome.
Advertisement
Latest Updated Articles
Venetoclax Plus Dose-Adjusted R-EPOCH Shows Promise for Richter’s SyndromePublished: June 21st 2020 | Updated:
Matthew Steven Davids, MD, MMSc on Venetoclax Plus R-EPOCH in Hematologic CancersPublished: July 11th 2020 | Updated:
Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s SyndromePublished: July 26th 2020 | Updated:
Matthew Steven Davids, MD, MMSc, Discusses a Phase II Study for Richter’s SyndromePublished: June 12th 2020 | Updated:
Matthew Steven Davids, MD, MMSc, on Venetoclax Plus R-EPOCH to Treat Richter’s SyndromePublished: June 1st 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
